Foundayo (Orforglipron) Week-by-Week (2026): Days 1-90 Titration Schedule, What to Expect & Common Questions

Foundayo (orforglipron) follows a strict 30-day-per-step titration ladder: 0.8 mg → 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → 17.2 mg. The starting dose is the smallest pill in the box. Every escalation requires at least 30 days on the current dose first, per verbatim §2 of the DailyMed FDA label (SetID 8ac446c5-feba-474f-a103-23facb9b5c62). This is the calendar-style guide to Days 1-90 — what each dose feels like, what the §6 adverse-reaction rates are at the top dose, the verbatim missed-dose recovery rule, and what ATTAIN-1 (NEJM 2025, PMID 40960239) and ATTAIN-2 (Lancet 2026, PMID 41275875) showed at 72 weeks.

The 90-day ladder at a glance

Verbatim §2 DOSAGE AND ADMINISTRATION text from the DailyMed label:

“The starting dosage is 0.8 mg orally once daily. After at least 30 days on the 0.8 mg dosage, increase the dosage to 2.5 mg once daily. After at least 30 days on the 2.5 mg dosage, increase the dosage to 5.5 mg once daily. The dosage may be increased to the next dosage level (9 mg, 14.5 mg, or 17.2 mg once daily) after at least 30 days on the current dosage, based on treatment response and tolerability. The maximum dosage of FOUNDAYO is 17.2 mg once daily.”

How to take Foundayo each day

Verbatim §2 administration instructions:

• “Take FOUNDAYO orally once daily, with or without food.” (Lilly's patient-facing materials add “with or without water” — the label says nothing about water requirements.)
• “Swallow tablets whole. Do not break, crush, or chew.”
• “Do not take more than one tablet per day.” Each dose strength is supplied as a different physical pill (color-coded). At every escalation, the box changes — only take the current strength, not multiple older strengths.

Practical tips that fall out of the label without contradicting it:

• Pick a time of day you can keep consistent. Once-daily dosing is most reliable when anchored to an existing habit (morning coffee, brushing teeth, evening pill box).
• Foundayo's GI side effects are dose-dependent, so taking it consistently at the same time matters less for efficacy than for habit reliability — there's no published evidence of a “best” time.
• Dispose of your prior-strength box when you transition. Pill confusion is the most common patient-reported error.
• Refrigeration is not required. Foundayo is a stable oral tablet, unlike injectable GLP-1s. Storage instructions per §16: room temperature, away from moisture and heat.

The missed-dose rule (verbatim)

Verbatim §2 missed-dose language from the DailyMed label:

“If a dose is missed, instruct patients to take the dose as soon as possible. If 7 or more consecutive doses are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions.”

Translation: missing a single day is recoverable — take it as soon as you remember. But missing 7 or more consecutive days resets the titration. After a 7+ day gap, you do not just resume your previous dose; you and your prescriber drop back to a lower dose and re-titrate. This is unique to Foundayo — weekly injectable GLP-1s have different missed-dose rules (Wegovy / Zepbound have separate language for missing a weekly shot). For the broader missed-dose framework across every GLP-1, see our missed-dose decision guide.

Days 1-30: the 0.8 mg starting month

The 0.8 mg dose is a starting / acclimation dose, not a therapeutic dose. Most patients on 0.8 mg do not experience meaningful weight loss; the trials showed minor effects at this dose. Its job is to introduce the GLP-1 receptor system gradually, reducing the GI shock that comes with starting higher.

What the published evidence and label tell us to expect:

• Mild GI symptoms are likely but not severe. The §6 ADVERSE REACTIONS table reports rates at the top 17.2 mg dose; at 0.8 mg the rates are substantially lower. Nausea, intermittent constipation, mild appetite reduction, and small early-satiety effects are typical.
• Appetite changes may be subtle. Some patients notice meaningfully reduced food preoccupation even at 0.8 mg; others notice almost nothing until the 5.5 mg step. Both are normal.
• No meaningful scale change is expected. Lilly's phase 2 dose-finding data showed weight loss starts to emerge around 2.5-5.5 mg. If you are not losing weight at 0.8 mg, that is not a treatment failure.
• Hydrate proactively. Slowed gastric emptying makes dehydration easier; the §5.4 warning about acute kidney injury due to volume depletion applies even at low doses.
• Watch for the §4 contraindication signals: severe abdominal pain (pancreatitis), severe persistent right-upper-quadrant pain (gallbladder), allergy/ angioedema. Call your prescriber, not Reddit.

Days 31-60: the 2.5 mg first step-up

After at least 30 days on 0.8 mg, the prescriber escalates to 2.5 mg/day. This is the first step where most patients notice clearer effects.

• GI symptoms can re-spike at the dose change — the “hump” pattern. Most patients see nausea / occasional vomiting in the first 1-2 weeks after the step, then stabilize. If nausea is severe past week 2 of the new dose, call your prescriber to discuss whether to hold or extend the step.
• Appetite reduction becomes more obvious. Many patients notice a clear difference between 0.8 mg and 2.5 mg in food preoccupation, meal-size satisfaction, and snacking frequency.
• Early scale movement may appear in the 1-3% range — but variable. The trial data anchors weight loss to the 5.5 mg dose and above.
• Constipation often surfaces here. Fiber, fluid, and movement are first-line. See our constipation management evidence guide for the published-evidence-anchored options.
• Hydration matters more. Increased GI slowing on 2.5 mg vs 0.8 mg amplifies the dehydration risk. Aim for steady, not bolus, fluid intake.

Days 61-90: the 5.5 mg first maintenance-eligible dose

The 5.5 mg dose is the first step at which the FDA label treats Foundayo as therapeutic for weight management. The §14 CLINICAL STUDIES results from ATTAIN-1 (Trial 1) at this dose, at 72 weeks vs placebo:

• 5.5 mg: −7.4% body weight (Δ vs placebo −5.3%)
• 9 mg: −8.3% (Δ −6.2%)
• 17.2 mg: −11.1% (Δ −9.0%)
• Placebo: −2.1% (baseline 103.9 kg / ~229 lb)

What to expect during Days 61-90:

• Continued weight loss in the 1-2% per month range for many patients. This is not the rapid loss curve of Zepbound 15 mg or Wegovy 2.4 mg; Foundayo's top-line weight loss at 17.2 mg (−11.1%) is below tirzepatide (~20.9% on SURMOUNT-1) and below semaglutide 2.4 mg (~14.9% on STEP-1).
• GI tolerability typically improves. Most patients report fewer GI side effects at 5.5 mg by week 4 than at the 2.5 mg dose-change spike — the pattern is step-up-and-stabilize, not continuous worsening.
• The next escalation decision becomes patient-specific. Some patients hold at 5.5 mg long-term because they are losing weight at a satisfactory rate with good tolerability. Others escalate to 9 mg, 14.5 mg, or 17.2 mg over the following months. The label explicitly anchors escalation to “treatment response and tolerability” — not a fixed timeline.
• Day-90 prescriber check-in. Most plans require a 90-day visit for prior-authorization renewal + weight + side-effect documentation. Bring your weight log and your symptom timeline.

Full §6 ADVERSE REACTIONS rates (top 17.2 mg dose vs placebo)

These are the worst-case rates — patients on 0.8, 2.5, or 5.5 mg generally see lower rates. From §6 Table 1 of the DailyMed label, FOUNDAYO 17.2 mg vs placebo:

Boxed warning, contraindications, and §5 monitoring

Foundayo carries a class-wide GLP-1 boxed warning for thyroid C-cell tumors. Verbatim §4 contraindications:

“FOUNDAYO is contraindicated in patients with: A personal or family history of MTC or in patients with MEN 2. Known serious hypersensitivity to orforglipron or any of the excipients in FOUNDAYO.”

§5 WARNINGS AND PRECAUTIONS subsections to monitor on each escalation:

• 5.1 Thyroid C-cell tumors (BBW)
• 5.2 Acute pancreatitis — severe persistent abdominal pain with or without vomiting; discontinue immediately if suspected
• 5.3 Severe gastrointestinal reactions — dehydration, hypovolemia
• 5.4 Acute kidney injury due to volume depletion — including reports of hemodialysis
• 5.5 Hypoglycemia — particularly in patients on insulin or sulfonylureas
• 5.6 Hypersensitivity reactions — including anaphylaxis and angioedema
• 5.7 Diabetic retinopathy complications in T2D patients with rapid glucose improvement
• 5.8 Acute gallbladder disease — increased incidence reported with GLP-1 RA class
• 5.9 Pulmonary aspiration during general anesthesia or deep sedation — Foundayo delays gastric emptying. See our ASA pre-op stop-date guide for the multisociety guidance on holding GLP-1s before surgery

What if my dose isn't working?

Common patient questions in the first 90 days:

• “I'm on 0.8 mg and have lost no weight” — expected. 0.8 mg is the starting dose; the trial weight-loss curve emerges at 2.5-5.5 mg.
• “I've been on 2.5 mg for 30 days; do I have to escalate?” — no. The label says at least 30 days, not exactly 30 days. Some patients hold at lower doses for longer to manage GI symptoms or to extend the response. Discuss with your prescriber.
• “I'm at 5.5 mg and weight loss has stalled” — variable. Some patients respond to escalation to 9 mg or higher; some respond to non-dose interventions (protein, strength training, sleep, stress). The published trial response distribution is wide; not every patient hits −11% at 17.2 mg.
• “I missed 5 days while traveling” — under 7 missed days, the §2 missed-dose rule says resume as soon as possible. 7+ days requires re-titration from a lower dose.
• “Can I switch from Zepbound to Foundayo?” — see our companion Foundayo ↔ Zepbound dose-equivalence guide for the FDA-label dose-range comparison. There is no FDA- approved equivalence; switching is a prescriber decision.

Bottom line

Foundayo's first 90 days follow a fixed, simple structure: 0.8 mg for at least 30 days, then 2.5 mg for at least 30 days, then 5.5 mg as the first therapeutic dose. Most patients see GI symptoms peak briefly at each step-up and stabilize within 1-2 weeks; meaningful weight loss generally appears at 5.5 mg and above; the 72-week trial efficacy at the top 17.2 mg dose is −11.1% body weight (ATTAIN-1, PMID 40960239). The only stop-and-restart rule patients need to memorize: 7 or more consecutive missed doses requires re-titration from a lower dose — single missed days are recoverable. Foundayo is the first FDA-approved oral GLP-1 RA in the weight- management indication and changes the access landscape; whether it's the right choice vs an injectable is a prescriber conversation anchored to your trial-readiness, GI tolerance, target weight loss, and access channel.

Related research

• How to take Foundayo (general patient guide)
• Foundayo vs Wegovy vs Zepbound full comparison
• Foundayo ↔ Zepbound switch dose-equivalence guide
• Foundayo FDA approval (regulatory deep dive)
• GLP-1 pills 2026: Rybelsus vs Foundayo vs Wegovy oral comparison
• Orforglipron / Foundayo side effects
• GLP-1 nausea management practical guide
• GLP-1 missed-dose decision guide (whole class)
• ASA anesthesia stop-date guide
• Foundayo drug page
• GLP-1 medications pillar (every approved + investigational agent)